Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio

Summary by CNHI News
FORT WORTH, Texas, Dec. 17, 2025 /PRNewswire/ -- NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of David Arthur as Chief Executive Officer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

CNHI NewsCNHI News

NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio

FORT WORTH, Texas, Dec. 17, 2025 /PRNewswire/ -- NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of David Arthur as Chief Executive Officer.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

CNHI News broke the news in United States on Wednesday, December 17, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Fort Worth icon

Fort Worth

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal